Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0013841017
Tue, 12.11.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand
2,000m2 of manu [ … ]
Thu, 24.10.2024
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Outlook 2024 confirmed: Flat year-on-year sales in CER and a CORE EBITDA margin of high 20s
Strong commercial and operational performance across the CDMO business in Q3; demand remains soft in Capsules & Health Ingredients and Bioscience businesses
Successful completion of the acquisition o [ … ]
Tue, 22.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership/Agreement
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates 22.10.2024 / 07:00 CET/CEST
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and [ … ]
Thu, 03.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST
David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors
Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting
Basel, Sw [ … ]
Tue, 01.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Acquisition
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST
The Vacaville site is one of the largest biologics manufacturing facilities in the world
Acquisition extends Lonza’s US Biologics footprint with a significant presence on [ … ]
Tue, 24.09.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST
Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply
CASGEVY® will be manufactured at Lonza [ … ]
Wed, 28.08.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds 28.08.2024 / 18:31 CET/CEST
Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds. [ … ]
Thu, 25.07.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members 25.07.2024 / 07:00 CET/CEST
Basel, Switzerland, 25 July 2024 - Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to [ … ]
Thu, 25.07.2024
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Lonza delivered sales of CHF 3.1 billion, growing 1.8%1 CER
CHF 893 million CORE EBITDA resulted in a margin of 29.2%
Robust performance in CDMO business, with headwinds in the capsules business within the Capsules & Health Ingredients (CHI) division
Solid free cash flow at CHF 296 million
Group O [ … ]
Mon, 01.07.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand 01.07.2024 / 07:00 CET/CEST
Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group
Albert M. Baehny will retire from Lonza Group following a transition period
Basel, Switzerland, 1 July 2024 – Wol [ … ]